Literature DB >> 15319823

Inhibins, activins, and follistatin in the aging female and male.

Joshua M Hurwitz1, Nanette Santoro.   

Abstract

Dimeric inhibins, activins, and follistatin (FS) were all initially characterized as reproductive endocrine hormones that regulate follicle-stimulating hormone (FSH) secretion. This model, however, has expanded under the weight of current medical evidence. Activin appears to play a central auto/paracrine role in reproductive and nonreproductive tissues. Inhibin and FS each have important counterregulatory functions in activin signaling. With reproductive aging, inhibin B declines along with the follicular pool and disturbs the dynamics of the normal menstrual cycle of midreproductive age. The loss of inhibin restraint of FSH secretion appears to be the initiating endocrine event that leads to menstrual cycle shortening and some of the hormonal unpredictability of the late reproductive years. It may also be related to the decline in fertility that occurs in reproductive aging. In men, inhibin B is an excellent marker for gonadal competence, and the decline of inhibin B with age reflects decreased gonadal reserve in both sexes. Circulating activin increases with aging, but its effect on reproduction in women and men is not clear. FS does not appear to change greatly with aging in men or women. The age-related fluctuations in this delicately balanced regulatory triad influence reproductive capacity and the sequelae of chronological aging. Elucidation of the molecular pathways responsible for the action of these hormones may allow closer integration with their current conceptual roles in aging.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319823     DOI: 10.1055/s-2004-831896

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  7 in total

1.  Loss of BMPR2 leads to high bone mass due to increased osteoblast activity.

Authors:  Jonathan W Lowery; Giuseppe Intini; Laura Gamer; Sutada Lotinun; Valerie S Salazar; Satoshi Ote; Karen Cox; Roland Baron; Vicki Rosen
Journal:  J Cell Sci       Date:  2015-02-06       Impact factor: 5.285

2.  Regulation of muscle mass by follistatin and activins.

Authors:  Se-Jin Lee; Yun-Sil Lee; Teresa A Zimmers; Arshia Soleimani; Martin M Matzuk; Kunihiro Tsuchida; Ronald D Cohn; Elisabeth R Barton
Journal:  Mol Endocrinol       Date:  2010-09-01

Review 3.  Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin.

Authors:  Kristy M Nicks; Daniel S Perrien; Nisreen S Akel; Larry J Suva; Dana Gaddy
Journal:  Mol Cell Endocrinol       Date:  2009-07-15       Impact factor: 4.102

4.  Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells.

Authors:  Matthew Bowser; Samuel Herberg; Phonepasong Arounleut; Xingming Shi; Sadanand Fulzele; William D Hill; Carlos M Isales; Mark W Hamrick
Journal:  Exp Gerontol       Date:  2012-11-21       Impact factor: 4.032

Review 5.  Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech.

Authors:  Rogério de Barros F Leão; Sandro C Esteves
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

Review 6.  Ovarian Aging: Role of Pituitary-Ovarian Axis Hormones and ncRNAs in Regulating Ovarian Mitochondrial Activity.

Authors:  Marco Colella; Danila Cuomo; Teresa Peluso; Ilaria Falanga; Massimo Mallardo; Mario De Felice; Concetta Ambrosino
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-16       Impact factor: 5.555

7.  Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation.

Authors:  Joel S Finkelstein; Hang Lee; Arun Karlamangla; Robert M Neer; Patrick M Sluss; Sherri-Ann M Burnett-Bowie; Karin Darakananda; Patricia K Donahoe; Sioban D Harlow; Sarah H Prizand; Hadine Joffe; Ajay Kumar; Deborah E Martin; Daniel McConnell; Steffenie Merrilat; Anthony Morrison; Lisa M Pastore; John F Randolph; Gail A Greendale; Nanette Santoro
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 6.134

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.